BriaCell Therapeutics Corp.
General ticker "BCTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $28.0M (TTM average)
BriaCell Therapeutics Corp. does not follow the US Stock Market performance with the rate: -28.3%.
Estimated limits based on current volatility of 3.3%: low 3.26$, high 3.48$
Factors to consider:
- Total employees count: 18 (+12.5%) as of 2024
- Top business risk factors: Going concern, Insufficient funding, Economic downturns and volatility, Third-party risks, Labor/talent shortage/retention
- Current price 58.7% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-07-31 to 2027-07-31
- 2025-07-31 to 2026-07-31 estimated range: [8.02$, 30.96$]
- 2026-07-31 to 2027-07-31 estimated range: [5.05$, 19.05$]
Financial Metrics affecting the BCTX estimates:
- Negative: with PPE of -0.1 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -50.70 <= -14.17
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Industry earnings per price (median), % of -18.81 <= 0
- Negative: negative Industry operating income (median)
- Positive: Interest expense per share per price, % of 0.34 <= 0.73
- Negative: Shareholder equity ratio, % of 82.59 > 64.29
Short-term BCTX quotes
Long-term BCTX plot with estimates
Financial data
| YTD | 2023-07-31 | 2024-07-31 | 2025-07-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $31.08MM | $46.27MM | $27.20MM |
| Operating Income | $-31.08MM | $-46.27MM | $-27.20MM |
| Non-Operating Income | $3.97MM | $39.42MM | $0.65MM |
| Interest Expense | $0.00MM | $0.00MM | $0.05MM |
| R&D Expense | $20.48MM | $37.73MM | $29.50MM |
| Income(Loss) | $-27.11MM | $-6.85MM | $-26.56MM |
| Net Income(Loss)* | $-26.96MM | $-6.51MM | $-26.31MM |
| Stockholders Equity | $-5.04MM | $-3.31MM | $24.58MM |
| Assets | $36.28MM | $8.15MM | $29.77MM |
| Operating Cash Flow | $-23.74MM | $-24.13MM | $-28.17MM |
| Capital expenditure | $0.00MM | $0.62MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-0.68MM | $-7.65MM |
| Financing Cash Flow | $3.95MM | $4.42MM | $45.45MM |
| Earnings Per Share** | $-25.89 | $-5.94 | $-13.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.